NewAmsterdam Pharma announced the closing of its upsized public offering, which included the full exercise of the underwriters' option to purchase additional shares. The offering generated approximately $452.6 million in net proceeds for the company after deducting underwriting discounts and commissions and estimated offering expenses.
The offering comprised 14,667,347 ordinary shares at a public offering price of $24.50 per share, and 4,882,653 pre-funded warrants at $24.4999 per pre-funded warrant. This successful capital raise significantly enhances NewAmsterdam Pharma's financial position.
The substantial net proceeds provide NewAmsterdam Pharma with a robust financial runway to fund its ongoing operations, advance its clinical development programs for obicetrapib, and prepare for potential commercialization in key markets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.